Summary:
This study compares the currently available medication for psoriasis called Ustekinumab (Brand name Stellara) to a new similar medication. This is a double blind study but there is NO Placebo which means ALL patients receive treatment with either the investigational medication or Ustekinumab! The study is 52 weeks long with a total of 9 visits. Qualified patients will be coming in for visits approximately once every 8-12 weeks on average.
Qualified Participants Must:
• Adult subjects including men and women between 18 to 75 years of age with moderate to sever plaque Psoriasis: Pregnant women are excluded from this trial
•
Even if you are on a current medication which is not fully effective in controlling your psoriasis symptoms you can still qualify for this trial
Qualified Participants May Receive:
Participants will receive compensation for time and travel for each visit. They will be evaluated by one of our physicians with a complete history and physical exam. Blood work will also be done for complete health evaluation. All exams and testing are complimentary and NO Health Insurance Necessary.